ATE524196T1 - An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür - Google Patents

An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Info

Publication number
ATE524196T1
ATE524196T1 AT02801760T AT02801760T ATE524196T1 AT E524196 T1 ATE524196 T1 AT E524196T1 AT 02801760 T AT02801760 T AT 02801760T AT 02801760 T AT02801760 T AT 02801760T AT E524196 T1 ATE524196 T1 AT E524196T1
Authority
AT
Austria
Prior art keywords
cancer
associated antigen
antibodies binding
antigen
mpa7
Prior art date
Application number
AT02801760T
Other languages
English (en)
Inventor
Jennie Mather
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE524196T1 publication Critical patent/ATE524196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02801760T 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür ATE524196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32964401P 2001-10-16 2001-10-16
PCT/US2002/033116 WO2003032814A2 (en) 2001-10-16 2002-10-16 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE524196T1 true ATE524196T1 (de) 2011-09-15

Family

ID=23286361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801760T ATE524196T1 (de) 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Country Status (6)

Country Link
US (2) US7148038B2 (de)
EP (1) EP1441766B1 (de)
JP (1) JP4347694B2 (de)
AT (1) ATE524196T1 (de)
CA (1) CA2463927A1 (de)
WO (1) WO2003032814A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032814A2 (en) 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20050226873A1 (en) * 2003-09-30 2005-10-13 Del Priore Lucian V Medical devices and methods for modulating cell adhesion
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US20080219981A1 (en) * 2004-03-29 2008-09-11 Hideki Shimada Diagnostic Kit for Solid Cancer and Medicament for Solid Cancer Therapy
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8309354B2 (en) * 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
SG172254A1 (en) 2008-12-19 2011-07-28 Macrogenics Inc Covalent diabodies and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
CN106434561A (zh) * 2010-09-03 2017-02-22 艾伯维施特姆森特克斯有限责任公司 细胞亚群的鉴定和富集
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US9567402B2 (en) * 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
EP3022227A1 (de) * 2013-07-19 2016-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Kombination aus einem ligand von hvem und einem immunotoxin zur verwendung in der therapie
CN111167008A (zh) 2013-12-05 2020-05-19 免疫系统公司 利用射频电学膜击穿（rf-emb）的癌症免疫疗法
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
CN114106179B (zh) * 2014-09-12 2025-04-08 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
CN105462935B (zh) * 2016-01-20 2017-08-04 潘世扬 抗卵巢癌单克隆抗体及其应用
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
CA3043277A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
SG11201907753TA (en) 2017-02-24 2019-09-27 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2019118266A1 (en) 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
WO2019160904A1 (en) 2018-02-15 2019-08-22 Macrogenics, Inc. Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2750220B2 (ja) 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
DK0678523T3 (da) 1993-01-14 2005-01-10 Chemo Sero Therapeut Res Inst Rekombinant anti-HIV antistof og fremstilling deraf
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
AU2077197A (en) 1996-03-18 1997-10-10 Novo Nordisk Biotech, Inc. Polypeptides having phytase activity and nucleic acids encoding same
ID20581A (id) 1996-10-18 1999-01-21 Res Fnd For Micbial Diseases O Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU2001261259A1 (en) 2000-05-12 2001-11-26 Anil K. Kaul Diagnostic method for screening complement regulatory protein levels
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1184458A1 (de) 2000-08-28 2002-03-06 U-BISys B.V. Unterschiedlich exprimierte CD46 Epitope, proteinartige Moleküle die fähig sind daran zu binden, und deren Verwendungen
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2003032814A2 (en) 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
JP4304309B2 (ja) * 2002-05-30 2009-07-29 レイベン バイオテクノロジーズ，インコーポレイティド 毒物学および投薬予測のための動物モデル
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer

Also Published As

Publication number Publication date
US7744878B2 (en) 2010-06-29
HK1064621A1 (en) 2005-02-04
JP2005511525A (ja) 2005-04-28
WO2003032814A3 (en) 2003-09-12
JP4347694B2 (ja) 2009-10-21
EP1441766B1 (de) 2011-09-14
CA2463927A1 (en) 2003-04-24
WO2003032814A2 (en) 2003-04-24
EP1441766A2 (de) 2004-08-04
US20030108966A1 (en) 2003-06-12
EP1441766A4 (de) 2006-03-08
US20070128202A1 (en) 2007-06-07
US7148038B2 (en) 2006-12-12

Similar Documents

Publication Publication Date Title
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DE602006013029D1 (de) Anti-egfr-antikörper
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
TW200510459A (en) RG1 antibodies and uses thereof
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
MXPA06010673A (es) Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
ATE414535T1 (de) Trägerproteine für impfstoffe
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2003064593A3 (en) Antigen panels and methods of using the same
WO2003080808A3 (en) Novel compositions and methods in cancer
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties